192 related articles for article (PubMed ID: 9499094)
21. Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
Cherry E; Slater M; Salomon H; Rud E; Wainberg MA
Antimicrob Agents Chemother; 1997 Dec; 41(12):2763-5. PubMed ID: 9420055
[TBL] [Abstract][Full Text] [Related]
22. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
Bazmi HZ; Hammond JL; Cavalcanti SC; Chu CK; Schinazi RF; Mellors JW
Antimicrob Agents Chemother; 2000 Jul; 44(7):1783-8. PubMed ID: 10858331
[TBL] [Abstract][Full Text] [Related]
23. Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.
Gobert JM; Remington KM; Zhu YQ; North TW
Antimicrob Agents Chemother; 1994 Apr; 38(4):861-4. PubMed ID: 8031060
[TBL] [Abstract][Full Text] [Related]
24. Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.
Murry JP; Higgins J; Matthews TB; Huang VY; Van Rompay KK; Pedersen NC; North TW
J Virol; 2003 Jan; 77(2):1120-30. PubMed ID: 12502828
[TBL] [Abstract][Full Text] [Related]
25. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.
von Wyl V; Ehteshami M; Symons J; Bürgisser P; Nijhuis M; Demeter LM; Yerly S; Böni J; Klimkait T; Schuurman R; Ledergerber B; Götte M; Günthard HF;
J Infect Dis; 2010 Apr; 201(7):1054-62. PubMed ID: 20170373
[TBL] [Abstract][Full Text] [Related]
26. 3'-Azido-3'-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1.
Mansky LM; Bernard LC
J Virol; 2000 Oct; 74(20):9532-9. PubMed ID: 11000223
[TBL] [Abstract][Full Text] [Related]
27. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA
J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
[TBL] [Abstract][Full Text] [Related]
28. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
[TBL] [Abstract][Full Text] [Related]
29. YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro.
Boyer PL; Gao HQ; Clark PK; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2001 Jul; 75(14):6321-8. PubMed ID: 11413298
[TBL] [Abstract][Full Text] [Related]
30. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.
Gu Z; Fletcher RS; Arts EJ; Wainberg MA; Parniak MA
J Biol Chem; 1994 Nov; 269(45):28118-22. PubMed ID: 7525567
[TBL] [Abstract][Full Text] [Related]
31. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Gu Z; Gao Q; Fang H; Salomon H; Parniak MA; Goldberg E; Cameron J; Wainberg MA
Antimicrob Agents Chemother; 1994 Feb; 38(2):275-81. PubMed ID: 7514855
[TBL] [Abstract][Full Text] [Related]
32. Chimeric HIV-1 and feline immunodeficiency virus reverse transcriptases: critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerases.
Amacker M; Hübscher U
J Mol Biol; 1998 May; 278(4):757-65. PubMed ID: 9614940
[TBL] [Abstract][Full Text] [Related]
33. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
Balzarini J; Pelemans H; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
Mol Pharmacol; 1996 May; 49(5):882-90. PubMed ID: 8622638
[TBL] [Abstract][Full Text] [Related]
34. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.
Boucher CA; Cammack N; Schipper P; Schuurman R; Rouse P; Wainberg MA; Cameron JM
Antimicrob Agents Chemother; 1993 Oct; 37(10):2231-4. PubMed ID: 7504909
[TBL] [Abstract][Full Text] [Related]
35. Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC.
Girouard M; Diallo K; Marchand B; McCormick S; Götte M
J Biol Chem; 2003 Sep; 278(36):34403-10. PubMed ID: 12819190
[TBL] [Abstract][Full Text] [Related]
36. Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination.
Chan SS; Santos JH; Meyer JN; Mandavilli BS; Cook DL; McCash CL; Kissling GE; Nyska A; Foley JF; van Houten B; Copeland WC; Walker VE; Witt KL; Bishop JB
Environ Mol Mutagen; 2007; 48(3-4):190-200. PubMed ID: 16395692
[TBL] [Abstract][Full Text] [Related]
37. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
[TBL] [Abstract][Full Text] [Related]
38. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
[TBL] [Abstract][Full Text] [Related]
39. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.
Hooker DJ; Tachedjian G; Solomon AE; Gurusinghe AD; Land S; Birch C; Anderson JL; Roy BM; Arnold E; Deacon NJ
J Virol; 1996 Nov; 70(11):8010-8. PubMed ID: 8892925
[TBL] [Abstract][Full Text] [Related]
40. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
